Dr. David Cherney
Claim this profileToronto General Hospital
Studies Kidney Disease
Studies Diabetes Mellitus
6 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials David Cherney is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
Retatrutide
for Obesity
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Recruiting1 award Phase 32 criteria
More about David Cherney
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David Cherney has experience with
- Sotagliflozin
- Placebo
- Semaglutide
- Dapagliflozin
- Zibotentan
- Ambrisentan
Breakdown of trials David Cherney has run
Kidney Disease
Diabetes Mellitus
Diabetic Kidney Disease
Diabetic Retinopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Cherney specialize in?
David Cherney focuses on Kidney Disease and Diabetes Mellitus. In particular, much of their work with Kidney Disease has involved treating patients, or patients who are undergoing treatment.
Is David Cherney currently recruiting for clinical trials?
Yes, David Cherney is currently recruiting for 4 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that David Cherney has studied deeply?
Yes, David Cherney has studied treatments such as Sotagliflozin, Placebo, Semaglutide.
What is the best way to schedule an appointment with David Cherney?
Apply for one of the trials that David Cherney is conducting.
What is the office address of David Cherney?
The office of David Cherney is located at: Toronto General Hospital, Toronto, Ontario M5G 2N2 Canada. This is the address for their practice at the Toronto General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.